Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

795.12 +2.82 (+0.36%)
Official Closing Price Updated: 7:00 PM EDT, Jun 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Again
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys.... 
Via Benzinga
Great News for Eli Lilly Stock Investors!
Via The Motley Fool
Ireland: America’s Gateway to Europe – The $2 Trillion Investment Story
Via AB Newswire
Huge News for Eli Lilly Stock Investors!
Via The Motley Fool
The End Of The Diabetes Industry? This Small Cap Could Upend The Business Models of Pharma Giants
is it the end of the diabetes industry? Here's a small cap that could upend the business models of pharma giants... 
Via Benzinga
23andMe Finds A Big Biotech Buyer In $256 Million Bankruptcy Auction
The acquirer says it will continue 23andMe's consumer genome testing services. It acquired a number of programs, including the biobank. 
Via Investor's Business Daily
Topics Bankruptcy
The Nasdaq Just Soared 30% From Its 2025 Low: 3 Vanguard ETFs to Buy Now
Via The Motley Fool
Topics ETFs Economy Stocks
Why Is Eli Lilly Stock Crashing and Is It a Buying Opportunity?
Via The Motley Fool
Got $1,000 to Invest? Buy This Top Vanguard ETF and Never Look Back.
Via The Motley Fool
Topics ETFs
MarketBeat Week in Review – 05/12 - 05/16
Stocks had a strong week on a potential U.S.-China trade deal and cooler inflation data, but volatility may remain as investors shift focus to tax cuts 
Via MarketBeat
Topics Artificial Intelligence Economy Government
Eli Lilly Pulls Ahead Of Novo In Obesity Drug Gold Rush As New Players Crowd In
Eli Lilly has steadily gained market share against Novo's Wegovy which finds itself catching up. 
Via Talk Markets
If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today
Via Benzinga
Discover which S&P500 stocks are making waves on Friday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Friday as we examine the latest happenings in today's session. 
Via Chartmill
9 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Stocks Fight For Fifth Day Of Gains, Dollar Rebounds As Inflation Fears Go Haywire: What's Driving Markets Friday?
Wall Street fought for a fifth consecutive day of gains on Friday, with major indexes edging slightly higher by midday in New York as investors continued to digest the week's significant trade... 
Via Benzinga
Topics Economy
Explore the top gainers and losers within the S&P500 index in today's session.
Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session. 
Via Chartmill
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Wall Street Expects This Obesity Drug Stock to Skyrocket 35% Over the Next 12 Months
Via The Motley Fool
Eli Lilly Collaborates With Rznomics On Hearing Loss Treatment In $1.3 Billion Pact
Eli Lilly signs a global licensing deal with Rznomics to co-develop RNA-editing therapies for hearing loss, with potential deal value above $1.3 billion. 
Via Benzinga
Is It Time to Buy the Dip in Novo Nordisk Stock?
Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing 
Via MarketBeat
Topics Government
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
2 Stocks That Plummeted During President Trump's First 100 Days in Office, and Where They Could Be Headed
The stock market experienced quite a bit of volatility during President Donald Trump's first 100 days in office. 
Via The Motley Fool
Topics Artificial Intelligence Fraud Government
3 Market-Beating Stocks with Promising Prospects
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
LLY Q1 Earnings Call: Revenue Beats Expectations, Profit Guidance Trimmed Amid Price Pressures
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 45.2% year on year to $12.73 billion. The company expects the full... 
Via StockStory
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
Via Benzinga
Got $500? 1 Billionaire-Approved Vanguard Index Fund to Buy and Hold Forever
Investing in index funds can be an incredibly lucrative way to build wealth. 
Via The Motley Fool
Topics ETFs Economy
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.